Neurophth Therapeutics

Building a brighter future through innovative gene therapy

Wuhan, China · Founded 2016 · $237.6M raised

Biotech
Gene Therapy
Healthcare
Headquarters
Wuhan
Employees
201–500
Founded
2016
Business Model
B2B
Total Funding
$237.6M
Last Round
$95.0M Extension RoundAug 2023
Rounds
5

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Neurophth Therapeutics (纽福斯生物科技) is China's first gene therapy company focused on ophthalmic and neurological diseases. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and international operations, the company develops in-vivo AAV-based gene therapies targeting rare genetic eye conditions including Leber Hereditary Optic Neuropathy (LHON), autosomal dominant optic atrophy (ADOA), and other retinal diseases. Neurophth has received IND clearance from the FDA and Australian approval for its lead ophthalmic gene therapy Opvika.

Summary

Neurophth Therapeutics is a Biotech company based in Wuhan, China, founded in 2016. It has raised $237.6M in total across 5 rounds, most recently a $95.0M Extension Round in Aug 2023. Investors include InnoStar Venture (Fosun), Sequoia Capital and Northern Light Ventures.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundSeries C+Aug 2023
$95.0M

Sign up to see all 5 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Neurophth Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/neurophth-therapeutics"><img src="https://indexed.vc/api/badge/company/neurophth-therapeutics" alt="Neurophth Therapeutics on Indexed.vc" width="260" height="76" /></a>